Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Neurology

Michael Leviten
November 15, 2017 7:21 PM UTC

Mouse studies suggest inhibiting the eIF4E-eIF4G1 interaction could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a tool compound that inhibits the eIF4E-eIF4G1 interaction increased dendritic spine numbers in hippocampal neurons and decreased memory deficits compared with vehicle. Next steps include development of additional eIF4E-eIF4G1 inhibitors.

Onconova Therapeutics Inc. has ON 013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

New York University